MediciBio is dedicated to developing gene delivery system, a proprietary lipid-based delivery platform designed to enable the effective delivery of a wide range of genetic therapeutics, including mRNA, saRNA, siRNA, and ASO.
Leveraging this core technology, MediciBio is also advancing its own novel drug programs, focusing on the development of ASO and mRNA therapeutics as well as mRNA vaccines.
Lipid nanoparticle (LNP) technology is a clinically proven platform at the forefront of mRNA vaccines and siRNA therapeutics.
At MediciBio, we are pioneering next-generation LNPs to overcome the limitations of current systems, delivering safer, more efficient solutions that unlock the full potential of genetic medicine
